Elan to use Graffinity's fragment technology for drug discovery
This article was originally published in Scrip
Executive Summary
The German company Graffinity Pharmaceutical has entered into a collaboration with ElanPharmaceuticals, which becomes the latest partner for Graffinity's drug discovery technology, which identifies drug fragments that interact with drug targets. Graffinity will receive technology access fees and success payments for generating small molecules, particularly those with novel modes of action and chemistry, for Elan. Graffinity is also collaborating with Rigel, Amgen and Boehringer Ingelheim.